5,423 Shares in Illumina, Inc. $ILMN Acquired by Plato Investment Management Ltd

Plato Investment Management Ltd bought a new stake in Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 5,423 shares of the life sciences company’s stock, valued at approximately $948,000.

A number of other large investors have also recently bought and sold shares of ILMN. WCM Investment Management LLC increased its position in Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after buying an additional 1,851,848 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Illumina in the second quarter valued at $293,846,000. Invesco Ltd. lifted its position in shares of Illumina by 97.0% in the fourth quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock valued at $360,426,000 after acquiring an additional 1,352,731 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Illumina by 30.3% in the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after acquiring an additional 1,028,099 shares in the last quarter. Finally, Morgan Stanley boosted its stake in shares of Illumina by 66.0% during the fourth quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company’s stock valued at $331,710,000 after acquiring an additional 1,005,474 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Activity at Illumina

In other Illumina news, Director Keith A. Meister sold 457,858 shares of the stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the transaction, the director owned 2,372,694 shares of the company’s stock, valued at $474,776,069.40. This trade represents a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Scott D. Ericksen sold 1,500 shares of Illumina stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $150.10, for a total transaction of $225,150.00. Following the completion of the transaction, the chief accounting officer owned 14,946 shares in the company, valued at approximately $2,243,394.60. This trade represents a 9.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 1,415,351 shares of company stock worth $255,966,311. 2.90% of the stock is currently owned by company insiders.

Illumina Stock Down 2.5%

Shares of NASDAQ:ILMN opened at $188.29 on Wednesday. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The firm has a market cap of $28.43 billion, a price-to-earnings ratio of 35.13, a PEG ratio of 2.69 and a beta of 1.44. The stock’s 50-day moving average price is $185.05 and its two-hundred day moving average price is $151.10. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $207.00.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts forecast that Illumina, Inc. will post 5.36 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently commented on the company. Daiwa Securities Group upgraded Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective for the company in a research report on Thursday, May 14th. Barclays upped their target price on shares of Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a report on Friday, July 31st. TD Cowen raised their price target on shares of Illumina from $192.00 to $210.00 and gave the stock a “hold” rating in a research note on Friday, July 31st. Piper Sandler reiterated an “overweight” rating and set a $225.00 price target (up from $200.00) on shares of Illumina in a report on Monday, August 3rd. Finally, Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $188.40.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.